A new experimental pill, enlicitide, is showing remarkable promise in the fight against heart disease. A phase three clinical trial published in The New England Journal of Medicine revealed that the oral medication reduced levels of low-density lipoprotein (LDL) cholesterol – often referred to as “bad” cholesterol – by as much as 60%.
The findings offer a potential breakthrough for millions of Americans who struggle to manage their cholesterol levels, despite lifestyle modifications and existing treatments. If approved by the Food and Drug Administration, enlicitide could provide a significant new tool in preventing heart attacks and strokes, two leading causes of death in the United States. Currently, fewer than half of patients with established atherosclerotic cardiovascular disease reach recommended LDL cholesterol goals, highlighting the urgent need for more effective therapies.
The development of enlicitide builds on decades of research into the underlying mechanisms of cholesterol metabolism. Scientists have long understood the critical role LDL cholesterol plays in the development of cardiovascular disease. These cholesterol particles accumulate within artery walls in a process called atherosclerosis, gradually narrowing the vessels and restricting blood flow. Reducing LDL cholesterol is therefore a cornerstone of both preventing and treating heart disease.
A Legacy of Discovery: From Nobel Prize to Novel Therapies
The journey to enlicitide began with groundbreaking operate at UT Southwestern Medical Center. In 1985, Michael Brown, M.D., and Joseph Goldstein, M.D., were awarded the Nobel Prize in Physiology or Medicine for their discovery of the LDL receptor, a protein on liver cells responsible for removing LDL cholesterol from the bloodstream. This discovery paved the way for the development of statins, which remain the most widely prescribed cholesterol-lowering drugs today.
Further research, stemming from the Dallas Heart Study at UTSW, led by Helen Hobbs, M.D., and Jonathan Cohen, Ph.D., identified the PCSK9 protein. This protein regulates the number of LDL receptors, effectively controlling how efficiently the body clears cholesterol. Genetic variations that reduce PCSK9 production were found to correlate with naturally lower LDL cholesterol levels. This insight spurred the development of injectable PCSK9 inhibitors, such as evolocumab and alirocumab, which can also lower LDL cholesterol by approximately 60%.
Overcoming Barriers to Treatment
Despite the effectiveness of injectable PCSK9 inhibitors, their use has been limited by factors such as high costs and the need for administration via injection. “Even though these injectable treatments are highly effective, they are not widely used in everyday care,” explained Ann Marie Navar, M.D., Ph.D., a cardiologist and Associate Professor of Internal Medicine at UT Southwestern Medical Center, who led the enlicitide trial. “One likely reason is that these medications must be given as injections rather than taken as pills.”
How Enlicitide Works
Enlicitide offers a potentially simpler solution. Like the injectable PCSK9 inhibitors, it targets the PCSK9 pathway, binding to the protein in the bloodstream and enhancing the body’s ability to remove LDL cholesterol. However, enlicitide is administered orally, once daily, offering a more convenient option for patients.
Clinical Trial Results: Significant LDL Reduction
The phase three trial involved 2,909 participants with either established atherosclerosis or a high risk of developing it. Approximately two-thirds received enlicitide, even as the remaining participants received a placebo. Importantly, most participants were already taking statins, yet their average LDL cholesterol level remained at 96 milligrams per deciliter (mg/dl), exceeding recommended targets of 70 mg/dl for those with atherosclerosis and 55 mg/dl for those at risk.
After 24 weeks, patients taking enlicitide experienced an average LDL cholesterol reduction of about 60% compared to those on the placebo. The drug also demonstrated positive effects on other cardiovascular risk markers, including non-HDL lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a). These improvements were sustained for a full year of follow-up. “These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins,” Dr. Navar stated.
What’s Next?
Researchers are currently conducting another clinical trial to determine whether the observed reductions in LDL cholesterol will translate into a decrease in the incidence of heart attacks and strokes. The results of this ongoing trial will be crucial in determining the long-term clinical benefits of enlicitide.
This research represents a significant step forward in the ongoing effort to combat cardiovascular disease. As we learn more about the complex interplay of cholesterol metabolism, we move closer to developing more effective and accessible treatments for those at risk.
Have a question about this story? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
